Form 8-K - Current report:
SEC Accession No. 0001013762-25-003401
Filing Date
2025-03-27
Accepted
2025-03-27 16:30:23
Documents
14
Period of Report
2025-03-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0235584-8k_inmune.htm   iXBRL 8-K 24734
2 PRESS RELEASE, DATED MARCH 27, 2025 ea023558402ex99-1_inmune.htm EX-99.1 109854
  Complete submission text file 0001013762-25-003401.txt   325579

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20250327.xsd EX-101.SCH 3017
4 XBRL LABEL FILE inmb-20250327_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE inmb-20250327_pre.xml EX-101.PRE 22360
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0235584-8k_inmune_htm.xml XML 3678
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 25779831
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)